FAMOSAN 10MG Potahovaná tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

famosan 10mg potahovaná tableta

pro.med.cs praha a.s. array - 9064 famotidin - potahovaná tableta - 10mg - famotidin

FAMOSAN 20MG Potahovaná tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

famosan 20mg potahovaná tableta

pro.med.cs praha a.s. array - 9064 famotidin - potahovaná tableta - 20mg - famotidin

FAMOSAN 40MG Potahovaná tableta Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

famosan 40mg potahovaná tableta

pro.med.cs praha a.s. array - 9064 famotidin - potahovaná tableta - 40mg - famotidin

Cabometyx Evropská unie - čeština - EMA (European Medicines Agency)

cabometyx

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastická činidla - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.